カテゴリー： 世界, 医療/バイオ, FactMR

世界の気管支喘息治療市場2023-2033：治療薬別（長期喘息治療薬、即効性喘息治療薬）、投与経路別（吸入、経口、静脈内、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）

【英語タイトル】Asthma Treatment Market By Treatment (Long-term Asthma Control Medications, Quick-relief (Rescue) Medications), By Route of Administration (Inhaled, Oral, Intravenous, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Market Insights 2023 to 2033

FactMRが出版した調査資料（FACT23AP080）・商品コード：FACT23AP080
・発行会社（調査会社）：FactMR
・発行日：2023年1月25日
・ページ数：約170
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）USD4,500 ⇒換算￥684,000見積依頼/購入/質問フォーム
Global Site License（同一拠点内共有可）USD8,500 ⇒換算￥1,292,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Fact.MR社発行の最新調査レポートでは、世界の気管支喘息治療市場について2023年から2033年までの市場動向を分析・予測しています。当レポートは、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場展望、治療薬別（長期喘息治療薬、即効性喘息治療薬）分析、投与経路別（経口、吸入、静脈内、皮下）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況など、多面的な分析結果をまとめたものです。なお、企業情報として、AstraZeneca、Boehringer Ingelheim International GmbH、GlaxoSmithKline plcなどが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場展望
・世界の気管支喘息治療市場規模：治療薬別
　- 長期喘息治療薬の市場規模
　- 即効性喘息治療薬の市場規模
・世界の気管支喘息治療市場規模：投与経路別
　- 経口投与の市場規模
　- 吸入投与の市場規模
　- 静脈内投与の市場規模
　- 皮下投与の市場規模
・世界の気管支喘息治療市場規模：流通チャネル別
　- 病院薬局の市場規模
　- 小売薬局の市場規模
　- オンライン薬局の市場規模
・世界の気管支喘息治療市場規模：地域別
　- 北米の気管支喘息治療市場規模
　- ヨーロッパの気管支喘息治療市場規模
　- アジア太平洋の気管支喘息治療市場規模
　- 中南米の気管支喘息治療市場規模
　- 中東/アフリカの気管支喘息治療市場規模
・競争状況

本レポートには、各企業の製品ポートフォリオや主要戦略、包括的なSWOT分析などの要素を含む企業情報が含まれています。企業のプレゼンスは、全著名プレーヤーについてマッピングされ、マトリックスを通して提示されます。また、購読者に実用的な洞察を提供し、熟考して市場の状況を示し、気管支喘息治療における競争レベルを推測するのに役立ちます。

Asthma Treatment Market – Scope of Report

A recent study by Fact.MR on the asthma treatment market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering asthma treatment.

The study also provides the dynamics responsible for influencing the future status of the asthma treatment market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the asthma treatment market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of asthma treatment across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of asthma treatment during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).

Estimates at global and regional levels for asthma treatment are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global asthma treatment market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the asthma treatment market during the forecast period.

Country-specific valuation on demand for asthma treatment has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of asthma treatment, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering asthma treatment has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the asthma treatment domain.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

4.4. Global Market Analysis and Forecast, 2023–2027

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Reimbursement Scenario

    5.3. Disease Prevalence with Key Countries

6. Global Market Analysis and Forecasts, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        6.3.1. Long-term Asthma Control Medications

            6.3.1.1. Inhaled Corticosteroids

            6.3.1.2. Leukotriene Modifiers

            6.3.1.3. Long-acting Beta Agonists

            6.3.1.4. Combination Inhalers

            6.3.1.5. Theophylline

            6.3.1.6. Others (reslizumab, benralizumab, etc.)

        6.3.2. Quick-relief (rescue) Medications

            6.3.2.1. Short-acting Beta Agonists

            6.3.2.2. Ipratropium (Atrovent)

            6.3.2.3. Oral and Intravenous Corticosteroids

    6.4. Global Market Attractiveness, by Treatment Type

7. Global Market Analysis and Forecasts, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Market Value (US$) Forecast, by Route of Administration, 2023–2027

        7.3.1. Oral

        7.3.2. Inhaled

        7.3.3. Intravenous

        7.3.4. Subcutaneous

    7.4. Global Market Attractiveness, by Route of Administration

8. Global Market Analysis and Forecasts, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Market Attractiveness, by Distribution Channel

9. Global Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Global Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Market Attractiveness, by Region

10. North America Market Analysis and Forecast

    10.1. Introduction

    10.2. North America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        10.2.1. Long-term Asthma Control Medications

            10.2.1.1. Inhaled Corticosteroids

            10.2.1.2. Leukotriene Modifiers

            10.2.1.3. Long-acting Beta Agonists

            10.2.1.4. Combination Inhalers

            10.2.1.5. Theophylline

            10.2.1.6. Others (reslizumab, benralizumab, etc.)

        10.2.2. Quick-relief (rescue) Medications

            10.2.2.1. Short-acting Beta Agonists

            10.2.2.2. Ipratropium (Atrovent)

            10.2.2.3. Oral and Intravenous Corticosteroids

    10.3. North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        10.3.1. Oral

        10.3.2. Inhaled

        10.3.3. Intravenous

        10.3.4. Subcutaneous

    10.4. North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Market Attractiveness Analysis

        10.6.1. By Treatment Type

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country/Sub-region

11. Europe Market Analysis and Forecast

    11.1. Introduction

    11.2. Europe Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        11.2.1. Long-term Asthma Control Medications

            11.2.1.1. Inhaled Corticosteroids

            11.2.1.2. Leukotriene Modifiers

            11.2.1.3. Long-acting Beta Agonists

            11.2.1.4. Combination Inhalers

            11.2.1.5. Theophylline

            11.2.1.6. Others (reslizumab, benralizumab etc.)

        11.2.2. Quick-relief (rescue) Medications

            11.2.2.1. Short-acting Beta Agonists

            11.2.2.2. Ipratropium (Atrovent)

            11.2.2.3. Oral and Intravenous Corticosteroids

    11.3. Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        11.3.1. Oral

        11.3.2. Inhaled

        11.3.3. Intravenous

        11.3.4. Subcutaneous

    11.4. Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Market Attractiveness Analysis

        11.6.1. By Treatment Type

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Market Analysis and Forecast

    12.1. Introduction

    12.2. Asia Pacific Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        12.2.1. Long-term Asthma Control Medications

            12.2.1.1. Inhaled Corticosteroids

            12.2.1.2. Leukotriene Modifiers

            12.2.1.3. Long-acting Beta Agonists

            12.2.1.4. Combination Inhalers

            12.2.1.5. Theophylline

            12.2.1.6. Others (reslizumab, benralizumab etc.)

        12.2.2. Quick-relief (rescue) Medications

            12.2.2.1. Short-acting Beta Agonists

            12.2.2.2. Ipratropium (Atrovent)

            12.2.2.3. Oral and Intravenous Corticosteroids

    12.3. Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        12.3.1. Oral

        12.3.2. Inhaled

        12.3.3. Intravenous

        12.3.4. Subcutaneous

    12.4. Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Market Attractiveness Analysis

        12.6.1. By Treatment Type

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Market Analysis and Forecast

    13.1. Introduction

    13.2. Latin America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        13.2.1. Long-term Asthma Control Medications

            13.2.1.1. Inhaled Corticosteroids

            13.2.1.2. Leukotriene Modifiers

            13.2.1.3. Long-acting Beta Agonists

            13.2.1.4. Combination Inhalers

            13.2.1.5. Theophylline

            13.2.1.6. Others (reslizumab, benralizumab etc.)

        13.2.2. Quick-relief (rescue) Medications

            13.2.2.1. Short-acting Beta Agonists

            13.2.2.2. Ipratropium (Atrovent)

            13.2.2.3. Oral and Intravenous Corticosteroids

    13.3. Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        13.3.1. Oral

        13.3.2. Inhaled

        13.3.3. Intravenous

        13.3.4. Subcutaneous

    13.4. Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Market Attractiveness Analysis

        13.6.1. By Treatment Type

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Market Analysis and Forecast

    14.1. Introduction

    14.2. Middle East & Africa Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        14.2.1. Long-term Asthma Control Medications

            14.2.1.1. Inhaled Corticosteroids

            14.2.1.2. Leukotriene Modifiers

            14.2.1.3. Long-acting Beta Agonists

            14.2.1.4. Combination Inhalers

            14.2.1.5. Theophylline

            14.2.1.6. Others (reslizumab, benralizumab etc.)

        14.2.2. Quick-relief (rescue) Medications

            14.2.2.1. Short-acting Beta Agonists

            14.2.2.2. Ipratropium (Atrovent)

            14.2.2.3. Oral and Intravenous Corticosteroids

    14.3. Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        14.3.1. Oral

        14.3.2. Inhaled

        14.3.3. Intravenous

        14.3.4. Subcutaneous

    14.4. Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        14.5.1. GCC

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Market Attractiveness Analysis

        14.6.1. By Treatment Type

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Share Analysis, by Company (2022)

    15.2. Company Profiles

        15.2.1. AstraZeneca

        15.2.2. Boehringer Ingelheim International GmbH

        15.2.3. GlaxoSmithKline plc

        15.2.4. Novartis AG

        15.2.5. Teva Pharmaceutical Industries Ltd

        15.2.6. Sumitomo Dainippon Pharma Co., Ltd

        15.2.7. Merck & Co., Inc.

        15.2.8. F. Hoffmann-La Roche Ltd.

        15.2.9. Sanofi

        15.2.10. Mylan N.V.

Table 01: Pipeline Analysis

Table 02: Pipeline Analysis

Table 03: Pipeline Analysis

Table 04: Global Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 05: Global Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 06: Global Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 07: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 08: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 09: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033

Table 10: North America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 11: North America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 12: North America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 13: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 14: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 15: North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 16: Europe Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 17: Europe Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 18: Europe Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 19: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 20: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 22: Asia Pacific Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 23: Asia Pacific Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 24: Asia Pacific Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 25: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 26: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 27: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 28: Latin America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 29: Latin America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 30: Latin America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 31: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 32: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 33: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 35: Middle East & Africa Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 36: Middle East & Africa Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 37: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 38: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 39: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

★調査レポート[世界の気管支喘息治療市場2023-2033：治療薬別（長期喘息治療薬、即効性喘息治療薬）、投与経路別（吸入、経口、静脈内、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）] (コード：FACT23AP080)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の気管支喘息治療市場2023-2033：治療薬別（長期喘息治療薬、即効性喘息治療薬）、投与経路別（吸入、経口、静脈内、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のペプチド感染症治療薬市場2023-2033：治療薬別（テラプレビル、ボセプレビル）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界のペプチドベース心臓血管治療薬市場2023-2033：治療薬別（ビバリルジン、エプチフィバチド）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界のペプチド治療薬（メタボリックシンドローム用）市場2023-2033：治療薬別（リラグルチド、エキセナチド）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界の婦人科用治療薬市場（2023-2033)：疾患別（婦人科系がん、避妊、女性不妊症、更年期障害、多嚢胞性卵巣症候群（PCOS）、その他）、治療薬別（非ホルモン治療薬、ホルモン治療薬）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、種類別（ジェネリック、ブランド）、地域別
  • 世界のレビー小体型認知症治療薬市場2023-2033：治療薬別（コリンエステラーゼ阻害薬、抗精神病薬、カルビドパ・レボドパ、抗うつ薬、ベンゾジアゼピン、モダフィニル）、疾患別（レビー小体型認知症（DLB）、パーキンソン病、アルツハイマー病）、購入形態別（処方薬、市販薬）、流通チャネル別（病院薬局、小売薬局、ドラッグストア、オンライン薬局）、地域別
  • 世界のリンパ腫治療薬市場2023年-2032年：疾患種類別（ホジキンリンパ腫、非ホジキンリンパ腫）、治療種類別（免疫療法、化学療法、標的療法、放射線療法）、投与経路別（経口経路、注射）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 世界の急性呼吸窮迫症候群（ARDS）治療薬市場2023-2030：薬剤クラス別（血管収縮薬、気管支拡張薬、ステロイド、抗生物質、その他）、投与経路別（経口、注射、吸入）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、地域別
  • 世界の嚢胞性線維症デバイス市場2023-2033：治療方法別（薬物療法、デバイス）、投与経路別（経口、非経口）、流通チャネル別（病院、小売薬局＆ドラッグストア、オンライン薬局）、地域別
  • 世界の血栓溶解薬市場2023年-2032年：製品別（血栓溶解薬、抗血小板薬、抗凝固薬、その他）、疾患別（肺塞栓症、深部静脈血栓症、心房細動、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 世界のオピオイド使用障害（OUD）治療剤市場2022-2029：薬物クラス別（ブプレノルフィン、メタドン、ナルトレキソン）、投与経路別（経口、非経口）、流通チャネル別（病院薬局、小売薬局＆店舗、オンライン薬局）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆